Moreover, targeting of C5aR increases paclitaxel response in squamous cell carcinoma by reprogramming the immunosuppressive tumor immune microenvironment, thereby leading to improved CD8+ T cell-mediated antitumor immune response (306). Here, C5AR1 is linked to neoplasm.